Christopher Evernden
Overview
Explore the profile of Christopher Evernden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review
Wichart J, Yoeun P, Chin T, Evernden C, Berendonk C, Kerr J, et al.
Fundam Clin Pharmacol
. 2024 Jun;
38(5):862-882.
PMID: 38877814
Background: Pharmacologic management of mental health illnesses in patients receiving dialysis is complex and lacking data. Objective: Our objective was to synthesize published data for the treatment of depression, bipolar...
2.
Evernden C, Charrois T
Can Pharm J (Ott)
. 2024 Jan;
156(5):243-246.
PMID: 38222893
No abstract available.
3.
Metzger S, Evernden C, Bungard T, Bell G, Omar M
Can J Hosp Pharm
. 2023 Mar;
76(2):102-108.
PMID: 36998758
Background: In Alberta, pharmacists are eligible to obtain additional prescribing authority (APA). At the University of Alberta Hospital, a transition was made from a paper-based prescriber order entry system to...
4.
Evernden C, Giang I, Anderson M
Ment Health Clin
. 2021 Oct;
11(5):305-310.
PMID: 34621608
International schizophrenia guidelines endorse seeking the patient's preference for guiding antipsychotic therapy. There exists a small niche of patients who prefer, or are required to use, long-acting injectable antipsychotic medications...
5.
Luk T, Edwards B, Bates D, Evernden C, Edwards J
Can Fam Physician
. 2021 May;
67(5):342-344.
PMID: 33980626
No abstract available.
6.
Evernden C, Dowhan M, Dabas R, Chaudhry A, Kalra A, Dharmani-Khan P, et al.
Cytotherapy
. 2020 Jan;
22(1):27-34.
PMID: 31889628
Background: International guidelines for Pneumocystis jirovecii pneumonia (PJP) prevention recommend prophylaxis for ≥6 months following allogeneic hematopoietic cell transplantation, and longer in patients with graft-versus-host disease (GVHD) or on immunosuppressive...